Comparative in vitro activity of cefditoren and other antimicrobials against Enterobacteriaceae causing community-acquired uncomplicated urinary tract infections in women: a Spanish nationwide multicenter study
- PMID: 20542206
- DOI: 10.1016/j.diagmicrobio.2010.02.013
Comparative in vitro activity of cefditoren and other antimicrobials against Enterobacteriaceae causing community-acquired uncomplicated urinary tract infections in women: a Spanish nationwide multicenter study
Abstract
Cefditoren is a third-generation orally administered cephalosporin with a broad spectrum of activity against Gram-positive and Gram-negative bacterial species. After an oral 400-mg single dose, the mean concentrations in urine are 186.5 mg/L at 2 to 4 h and 12.7 mg/L at 8 to 12 h, and it is a potential drug to be used in the treatment of urinary tract infection (UTI). We performed a multicenter nationwide study in Spain in order to determine the in vitro activity of cefditoren and other comparative agents against Enterobacteriaceae causing community-acquired uncomplicated UTI in women. From June 2008 to March 2009, 89 institutions participated in the study. A total of 2152 Enterobacteriaceae were collected and sent to a coordinating laboratory where identification and antimicrobial susceptibility testing was performed against 20 antimicrobials using an automated microdilution method (MicroScan; Siemens, Sacramento, CA). Cefditoren MICs were determined by the broth microdilution method (Clinical and Laboratory Standards Institute guidelines) using the same inoculum. Microorganisms isolated were Escherichia coli (81.8%), Klebsiella pneumoniae (7.9%), Proteus mirabilis (5.2%), and others (5.1%). A total of 51 isolates (2.4%) were extended-spectrum beta-lactamase (ESBL) producers, 3 (0.1%) produced plasmidic AmpC enzymes, and 64 (2.9%) produced chromosomal AmpC. The MIC(50)/MIC(90) (mg/L) of cefditoren against all isolates was 0.12/0.5. Cefditoren inhibited 96.5% of isolates at 1 mg/L and was uniformly active against all isolates with the exception of strains producing ESBLs or AmpC enzymes. The MIC(50)/MIC(90) of other antimicrobials were ampicillin (AMP) >16/>16, amoxicillin/clavulanic acid (A/C) <or=8/4/16/8, cefuroxime (FUR) <or=4/8, cefotaxime <or=1/<or=1, ciprofloxacin (CIP) <or=0.12/>2, trimethoprim/sulfamethoxazole (SxT) <or=2/38/>4/76, and fosfomycin (FOS) <or=16/<or=16. The respective percentages of resistance were 61%, 17.2%, 5.5%, 2.3%, 20.2%, 27.4%, and 4.8%. The activity of cefditoren against Enterobacteriaceae producing community-acquired uncomplicated UTI in women was superior to that of AMP, A/C, FUR, CIP, and SxT and similar to that of FOS.
Similar articles
-
In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain.Diagn Microbiol Infect Dis. 2008 Oct;62(2):210-5. doi: 10.1016/j.diagmicrobio.2008.06.007. Epub 2008 Aug 20. Diagn Microbiol Infect Dis. 2008. PMID: 18715733
-
Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.Diagn Microbiol Infect Dis. 2009 Jun;64(2):202-12. doi: 10.1016/j.diagmicrobio.2009.01.017. Epub 2009 Mar 25. Diagn Microbiol Infect Dis. 2009. PMID: 19321284 Review.
-
Cefditoren: Comparative efficacy with other antimicrobials and risk factors for resistance in clinical isolates causing UTIs in outpatients.BMC Infect Dis. 2012 Sep 25;12:228. doi: 10.1186/1471-2334-12-228. BMC Infect Dis. 2012. PMID: 23009290 Free PMC article.
-
[Patterns of susceptibility to antibiotics of Enterobacteriaceae causing intra-abdominal infection in Spain: SMART 2003 study outcomes].Rev Esp Quimioter. 2006 Mar;19(1):51-9. Rev Esp Quimioter. 2006. PMID: 16688292 Spanish.
-
Resistance in gram-negative bacteria: enterobacteriaceae.Am J Med. 2006 Jun;119(6 Suppl 1):S20-8; discussion S62-70. doi: 10.1016/j.amjmed.2006.03.013. Am J Med. 2006. PMID: 16735147 Review.
Cited by
-
Proteus mirabilis and Klebsiella pneumoniae as pathogens capable of causing co-infections and exhibiting similarities in their virulence factors.Front Cell Infect Microbiol. 2022 Oct 20;12:991657. doi: 10.3389/fcimb.2022.991657. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36339335 Free PMC article. Review.
-
The Contribution of Polysaccharide Antigens From Clinical Proteus spp. and Klebsiella spp. Isolates to the Serological Cross-Reactions.Front Cell Infect Microbiol. 2021 Aug 26;11:707578. doi: 10.3389/fcimb.2021.707578. eCollection 2021. Front Cell Infect Microbiol. 2021. PMID: 34513729 Free PMC article.
-
Escherichia coli Resistance to Fluoroquinolones in Community-Acquired Uncomplicated Urinary Tract Infection in Women: a Systematic Review.Antimicrob Agents Chemother. 2020 Sep 21;64(10):e00862-20. doi: 10.1128/AAC.00862-20. Print 2020 Sep 21. Antimicrob Agents Chemother. 2020. PMID: 32747356 Free PMC article.
-
Community-Acquired Urinary Tract Infection by Escherichia coli in the Era of Antibiotic Resistance.Biomed Res Int. 2018 Sep 26;2018:7656752. doi: 10.1155/2018/7656752. eCollection 2018. Biomed Res Int. 2018. PMID: 30356438 Free PMC article. Review.
-
Clinical characteristics and outcomes of patients with extended-spectrum β-lactamase-producing bacteremias in the emergency department.Intern Emerg Med. 2011 Dec;6(6):547-55. doi: 10.1007/s11739-011-0707-3. Epub 2011 Oct 28. Intern Emerg Med. 2011. PMID: 22033790
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical